Advanced Technologies in Biopharmaceutical Processing

An increasing number of pharmaceuticals in human and veterinary medicine are being developed using advanced genetic and other methods that focus on modification of somatic and embryonic cells. These methods, in the setting of drug manufacture, call for new processes that go beyond the traditional unit processes of chemical and biological production, such as batch submerged culture.
The volume explains how technologies developed in the last decade function similarly to unit operations for producing advanced biopharmaceuticals, such as hormones, cytokines, therapeutic enzymes, modified proteins, and transgenic products – to name a few. From large–scale animal cell bioreactors to patient–customized products, this volume describes the effects of new technologies on biopharmaceutical processes and guides users on how to apply new technologies in process development.

Spis treści:
Contributors.
Preface.
Foreword.
Chapter 1: Overview of the Biopharmaceutical Industry.
Chapter 2: Regulatory Requirements for Processing Biopharmaceuticals.
Chapter 3: Genomics, Proteomics, and Metabolomics – Impact on Biopharmaceutical Processing.
Chapter 4: New Technologies in Biopharmaceutical Upstream Processing.
Chapter 5: New Technologies in Biopharmaceutical Downstream Processing.
Chapter 6: Biopharmaceutical Product Formulation, Preservation, and Presentation.
Chapter 7: Biopharmaceutical Product and Process Monitoring, Analysis and Control.
Chapter 8: Discrete Automation in BioProcessing Unit Operations.
Chapter 9: Emerging Biopharmaceutical Platforms.
Bibliography and Further Reading.
Index

Nota biograficzna:
Roshni Dutton Ph.D., Associate Professor, Dept. of Chemical Engineering, Ryerson University, Toronto, Canada and President, Bioprocess Assist (BPA) Ltd., Aberfoyle, Ontario, Canada
Jeno Scharer Ph.D. Professor Emeritus, Department of Chemical Engineering, University of Wa terloo, Canada

Okładka tylna:
An increasing number of pharmaceuticals in human and veterinary medicine are being developed using advanced genetic and other methods that focus on modification of somatic and embryonic cells. These methods, in the setting of drug manufacture, call for new processes that go beyond the traditional unit processes of chemical and biological production, such as batch submerged culture.
The volume explains how technologies developed in the last decade function similarly to unit operations for producing advanced biopharmaceuticals, such as hormones, cytokines, therapeutic enzymes, modified proteins, and transgenic products – to name a few. From large–scale animal cell bioreactors to patient–customized products, this volume describes the effects of new technologies on biopharmaceutical processes and guides users on how to apply new technologies in process development.